We get another mention...
"Over the years, various therapeutic strategies were explored to prevent HIV reservoir establishment and enhance early viral suppression. Broadly neutralizing monoclonal antibodies (bnAb) in clinical evaluation have been engineered for increased breadth and potency against HIV strains through high-dose formulations199, prolonged serum half-life through Fc engineering200, and enhanced transplacental delivery by optimizing FcRn-IgG interactions191. For example, leronlimab (CCR5 receptor-targeting) has shown promise in FcRn-enhanced formulations191. To date, 17 bnAbs in clinical development target conserved regions of the HIV envelope, including the CD4 binding site, V1-V3 glycans, membrane-proximal external region, gp120-gp41 interface, and the “silent face” epitope201,202. Next-generation strategies include combining long-acting bnAbs with ART to sustain viral suppression and limit immune activation189,201, mRNA-based nanoparticle vaccines, with prime-boost regimens promoting maturation of bnAb precursors203, gene editing tools, such as CRISPR-Cas9, targeting viral co-receptors (CCR5, CXCR4, and HIV LTR loci) for latent reservoirs eradication204,205, and immune checkpoint inhibitors to promote immune surveillance of residual infected cells206,207. While combinatorial approaches may be advantageous than single-agent blockade, the enhanced effect may increase the toxicity of certain strategies. Hence, these approaches must balance toxicity, immune rejection, off-target effects, viral tropism switching, and economic feasibility, particularly in resource-limited settings."
https://www.nature.com/articles/s44298-026-00174-9
12
